C16orf89 | Chromosome 16 open reading frame 89 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
C17orf47 | Chromosome 17 open reading frame 47 | | | | | | Tissue enriched |
C17orf78 | Chromosome 17 open reading frame 78 | Predicted membrane proteins
| | | | | Group enriched |
C19orf18 | Chromosome 19 open reading frame 18 | Predicted membrane proteins
| | | | | Tissue enriched |
C1orf167 | Chromosome 1 open reading frame 167 | | | | | | Group enriched |
C1orf170 | Chromosome 1 open reading frame 170 | | | | | | Tissue enhanced |
C1orf222 | Chromosome 1 open reading frame 222 | | | | | | Tissue enhanced |
C1QTNF6 | C1q and tumor necrosis factor related protein 6 | | | | | | Tissue enhanced |
C2 | Complement component 2 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
C21orf33 | Chromosome 21 open reading frame 33 | Mitochondrial proteins Predicted secreted proteins
| | | | | Expressed in all |
C2orf81 | Chromosome 2 open reading frame 81 | | | | | | Group enriched |
C2orf82 | Chromosome 2 open reading frame 82 | Predicted membrane proteins
| | | | | Tissue enhanced |
C4orf29 | Chromosome 4 open reading frame 29 | | | | | | Expressed in all |
C5AR2 | Complement component 5a receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
C5orf60 | Chromosome 5 open reading frame 60 | Predicted membrane proteins
| | | | | Tissue enriched |
C7orf61 | Chromosome 7 open reading frame 61 | | | | | | Tissue enriched |
CA12 | Carbonic anhydrase XII | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CACNA2D2 | Calcium channel, voltage-dependent, alpha 2/delta subunit 2 | FDA approved drug targets Transporters
| | | | | Tissue enriched |
CACNG8 | Calcium channel, voltage-dependent, gamma subunit 8 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CAD | Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase | Cancer-related genes Enzymes Plasma proteins
| | | | | Expressed in all |
CADM1 | Cell adhesion molecule 1 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
CADM2 | Cell adhesion molecule 2 | Predicted membrane proteins
| | | | | Tissue enriched |
CADM3 | Cell adhesion molecule 3 | Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
CADPS | Ca++-dependent secretion activator | Plasma proteins
| | | | | Tissue enhanced |
CALCOCO2 | Calcium binding and coiled-coil domain 2 | Cytoskeleton related proteins
| | | | | Expressed in all |
CAMK2A | Calcium/calmodulin-dependent protein kinase II alpha | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
CAMK2B | Calcium/calmodulin-dependent protein kinase II beta | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
CAMKK2 | Calcium/calmodulin-dependent protein kinase kinase 2, beta | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
CAMKV | CaM kinase-like vesicle-associated | Enzymes
| | | | | Tissue enriched |
CANT1 | Calcium activated nucleotidase 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
CANX | Calnexin | Cancer-related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CAPN5 | Calpain 5 | Disease related genes Enzymes Potential drug targets
| | | | | Mixed |
CARD8 | Caspase recruitment domain family, member 8 | Predicted membrane proteins
| | | | | Expressed in all |
CASC4 | Cancer susceptibility candidate 4 | | | | | | Expressed in all |
CASK | Calcium/calmodulin-dependent serine protein kinase (MAGUK family) | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CATSPER4 | Cation channel, sperm associated 4 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
CAV1 | Caveolin 1, caveolae protein, 22kDa | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CAV2 | Caveolin 2 | Predicted membrane proteins
| | | | | Mixed |
CAV3 | Caveolin 3 | Disease related genes Predicted membrane proteins
| | | | | Group enriched |
CCDC155 | Coiled-coil domain containing 155 | Predicted membrane proteins
| | | | | Tissue enriched |
CCDC51 | Coiled-coil domain containing 51 | Predicted membrane proteins
| | | | | Expressed in all |
CCDC57 | Coiled-coil domain containing 57 | | | | | | Expressed in all |
CCDC90B | Coiled-coil domain containing 90B | Mitochondrial proteins Predicted membrane proteins
| | | | | Expressed in all |